Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zooming From Zero To $400 Million: The Making of Mankind Pharma - India’s Fastest Growing Company

This article was originally published in PharmAsia News

Executive Summary

The head of India’s fastest-rising pharma company may be unconventional, but his willingness to take risks and do business differently has set the company on an upward trajectory.

You may also be interested in...

Global Pharma Bidders May Queue Up For A Slice Of Mankind Pharma And Scorching 25 Percent Growth

MUMBAI - India's Mankind Pharma, which has seen exponential year-on-year growth of more than 25 percent, may be the latest attraction for large multinational pharma companies as speculation gathers steam that its deep roots in the largely untapped semi-urban and rural markets makes it an enviable takeover target

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Lee Takes India Compulsory License Fight To Saxagliptin

In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts